Our goal in this study is to check HL patients for the expression of BCL-2, BCL-XL, BCL-W and MCL-1, check HL cell lines for the sensitivity to BH3 mimetics, and check if combination therapy with doxorubicin, as a first line treatment in HL, or tamoxifen is effective and if the effect can be predicted with dynamic BH3 profiling. Here, MCL1 is linked to Hodgkins lymphoma.